Glucagon-Like Peptide-1 Receptor Agonists and Survival in Head and Neck Squamous Cell Carcinoma

Importance Metformin has known metabolic effects and associated survival benefits in head and neck cancer. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) also modulate systemic metabolism through regulating blood glucose levels and lipid metabolism. Objective To investigate whether GLP-1RAs are associated with survival outcomes in patients with head and neck cancers. Design, Setting, and Participants This retrospective cohort study was conducted using clinical data from January 1, 1990, through December 1, 2025, from the TriNetX Global Collaborative Network. Adults with histologically confirmed head and neck squamous cell carcinomas (HNSCC) were included. Data were analyzed in January 2026. Main Outcomes and Measures The primary outcome was overall survival for all HNSCC and stratified by site. The secondary outcome was overall survival among patients concurrently using GLP-1RAs and metformin. Adjusted hazard ratios (aHRs) with 95% CIs were estimated. Results There were 4532 patients (mean [SD] age, 63.4 [10.9] years; 1638 female individuals [36.1%] and 2891 male individuals [63.8%]) included in the cohort. Across all subsites, GLP-1RA users had significantly improved overall survival compared with controls at 1-year (aHR, 0.42; 95% CI, 0.36-0.49), 3-year (aHR, 0.48; 95% CI, 0.43-0.54), and 5-year intervals (aHR, 0.51; 95% CI, 0.46-0.57). By anatomic subsite, GLP-1RA use remained consistently associated with a lower hazard of mortality at 5-year intervals (oral cavity: aHR, 0.60; 95% CI, 0.51-0.70; oropharynx: aHR, 0.51; 95% CI, 0.41-0.64; larynx: aHR, 0.49; 95% CI, 0.39-0.61). We also observed significant overall survival among patients who used GLP-1RAs and metformin at 1 year (aHR, 0.29; 95% CI, 0.23-0.36), 3 years (aHR, 0.36; 95% CI, 0.30-0.42) and 5 years (aHR, 0.39; 95% CI, 0.34-0.45). Conclusions The findings of this cohort study suggest that there may be survival benefits associated with GLP-1RA use among patients with HNSCC across several subsites. Future prospective and interventional studies of GLP-1RA potential metabolic adjuncts in oncologic care may help corroborate the associations from this retrospective study.

Authors

Institutions

Publication Details

Journal
JAMA Otolaryngology–Head & Neck Surgery
Published
2026-11-19
DOI
https://doi.org/10.1001/jamaoto.2026.3648
Primary Topic
Head and Neck Cancer Studies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Glucagon-Like Peptide-1 Receptor Agonists and Survival in Head and Neck Squamous Cell Carcinoma

Nosayaba Osazuwa‐Peters, Trinitia Y. Cannon, Daniel Uralov, Morgan C. Byrd et al.
JAMA Otolaryngology–Head & Neck Surgery
Head and Neck Cancer Studies
article

Glucagon-Like Peptide-1 Receptor Agonists and Survival in Head and Neck Squamous Cell Carcinoma

Nosayaba Osazuwa‐Peters, Trinitia Y. Cannon, Daniel Uralov, Morgan C. Byrd, Alexandra E. Hunter, Joseph Curry
article en

Abstract

Importance Metformin has known metabolic effects and associated survival benefits in head and neck cancer. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) also modulate systemic metabolism through regulating blood glucose levels and lipid metabolism. Objective To investigate whether GLP-1RAs are associated with survival outcomes in patients with head and neck cancers. Design, Setting, and Participants This retrospective cohort study was conducted using clinical data from January 1, 1990, through December 1, 2025, from the TriNetX Global Collaborative Network. Adults with histologically confirmed head and neck squamous cell carcinomas (HNSCC) were included. Data were analyzed in January 2026. Main Outcomes and Measures The primary outcome was overall survival for all HNSCC and stratified by site. The secondary outcome was overall survival among patients concurrently using GLP-1RAs and metformin. Adjusted hazard ratios (aHRs) with 95% CIs were estimated. Results There were 4532 patients (mean [SD] age, 63.4 [10.9] years; 1638 female individuals [36.1%] and 2891 male individuals [63.8%]) included in the cohort. Across all subsites, GLP-1RA users had significantly improved overall survival compared with controls at 1-year (aHR, 0.42; 95% CI, 0.36-0.49), 3-year (aHR, 0.48; 95% CI, 0.43-0.54), and 5-year intervals (aHR, 0.51; 95% CI, 0.46-0.57). By anatomic subsite, GLP-1RA use remained consistently associated with a lower hazard of mortality at 5-year intervals (oral cavity: aHR, 0.60; 95% CI, 0.51-0.70; oropharynx: aHR, 0.51; 95% CI, 0.41-0.64; larynx: aHR, 0.49; 95% CI, 0.39-0.61). We also observed significant overall survival among patients who used GLP-1RAs and metformin at 1 year (aHR, 0.29; 95% CI, 0.23-0.36), 3 years (aHR, 0.36; 95% CI, 0.30-0.42) and 5 years (aHR, 0.39; 95% CI, 0.34-0.45). Conclusions The findings of this cohort study suggest that there may be survival benefits associated with GLP-1RA use among patients with HNSCC across several subsites. Future prospective and interventional studies of GLP-1RA potential metabolic adjuncts in oncologic care may help corroborate the associations from this retrospective study.

JAMA Otolaryngology–Head & Neck Surgery
Thomas Jefferson University (US), Duke University (US), Duke Medical Center (US), Duke Cancer Institute (US)
Head and Neck Cancer Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon